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Hedgehog signaling plays a critical role in
embryonic development and
tumorigenesis. Here,Williams et al. report
the discovery of eggmanone, a selective
inhibitor of phosphodiesterase 4, and
show that PDE4 plays a key regulatory
role in Hedgehog signaling downstream
of Smoothened. Thus, PDE4 represents a
possible therapeutic target for
Hedgehog-dependent cancers.
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Hedgehog (Hh) signaling plays an integral role in
vertebrate development, and its dysregulation has
been accepted widely as a driver of numerous malig-
nancies. While a variety of small molecules target
Smoothened (Smo) as a strategy for Hh inhibition,
Smo gain-of-function mutations have limited their
clinical implementation. Modulation of targets down-
stream of Smo could define a paradigm for treatment
of Hh-dependent cancers. Here, we describe eggma-
none, a small molecule identified from a chemical
genetic zebrafish screen, which induced an Hh-null
phenotype. Eggmanone exerts its Hh-inhibitory ef-
fects through selective antagonism of phosphodies-
terase 4 (PDE4), leading to protein kinase A activation
and subsequent Hh blockade. Our study implicates
PDE4 as a target for Hh inhibition, suggests an
improved strategy for Hh-dependent cancer therapy,
and identifies a unique probe of downstream-of-Smo
Hh modulation.INTRODUCTION
Hedgehog (Hh) signaling represents an important therapeutic
target for the treatment of cancer. While its signal transduction
and resulting downstream gene transcription are essential to
vertebrate embryonic patterning and development, aberrant
Hh signaling is responsible for a variety of malignancies including
basal cell carcinoma (BCC), medulloblastoma, small cell lung
cancer, and pancreatic cancer (Kar et al., 2012; Ng and Curran,
2011). Classical Hh signaling requires the presence of the extra-cellular ligand Sonic hedgehog (Shh), which upon binding to the
transmembrane receptor Patched (Ptc) causes Ptc to remove its
inhibitory influence on the G protein-coupled receptor Smooth-
ened (Smo) (Ryan and Chiang, 2012). Activation of Smo then
leads to nuclear translocation of the Gli family of transcription
factors and induction of Hh target gene transcription. In the
absence of the hedgehog family of ligands, Gli-mediated tran-
scription is inhibited, and although numerous components of
signal transduction between Smo activation and Gli-mediated
gene transcription have been identified, their mechanism of
action is not fully understood.
A wide array of small molecules that target Smo, including
the canonical Hh inhibitor cyclopamine, have been shown to
affect tumor progression (Taipale et al., 2000; Carney and Ing-
ham, 2013). Additionally, the Smo antagonist vismodegib is
approved by the United States Food and Drug Administration
(FDA) for the treatment of advanced BCC (Robarge et al.,
2009; Von Hoff et al., 2009). However, oncogenic mutations
downstream of Smo and acquired resistance due to Smo-
binding pocket mutations have limited the efficacy of this and
other clinically promising therapeutics (Yauch et al., 2009).
Therefore, the identification of distal signaling mediators could
represent new therapeutic opportunities for Hh-dependent
malignancies.RESULTS
Discovery of Eggmanone, a Small Molecule Hedgehog
Inhibitor, from an In Vivo Chemical Genetic Screen
A screen of approximately 30,000 small molecules for their ability
to effect alterations in embryonic zebrafish patterning identified a
series of structurally related compounds represented by the
prototype termed eggmanone (Figures 1A and S1A–S1C; Sup-
plemental Experimental Procedures). Eggmanone reliably andCell Reports 11, 43–50, April 7, 2015 ª2015 The Authors 43
Figure 1. Eggmanone Affects Embryonic
Zebrafish Patterning through Inhibition of
Hedgehog Signaling




(B) Zebrafish embryos treated with 2 mM Egm
starting at 4 hr post fertilization (hrpf) exhibited a
range of phenotypes found in Hh pathway mu-
tants, including ventral tail curvature, loss of pec-
toral fins, and smaller eyes.
(C) Alcian blue staining following 2 mM Egm treat-
ment at 4 hrpf revealed altered craniofacial
development, including the jaw.
(D) Trunk slow muscles immunostained with anti-
MyHC antibody (F59) showed altered slow-mus-
cle formation upon Egm treatment (2 mM).
(E) Egm treatment (1 mM) abolished Hh-responsive
Ptc1 expression in adaxial cells at 12 hrpf (arrows).
(F) Egm treatment (1 mM) ablated Hh-responsive
Ptc1 expression in the pectoral fin bud at 48 hrpf
(arrows and asterisks).
(G) Egm inhibited Sonic hedgehog (Shh)-respon-
sive Gli-luciferase (Gli-Luc) reporter activity in a
dose-dependent manner when stimulated with
Shh-conditioned medium (n = 4 for each condition,
results represented asmean relative luciferaseunits
(RLU) ± SEM; p value < 0.0184, starting at 1 mM).
(H) Egm inhibited purmorphamine-induced (3 mM)
Gli-Luc reporter activity in a dose-dependent
manner (mean ± SEM, n = 4 for each condition;
p value < 0.0054, starting at 0.5 mM).
(I) Egm inhibited purmorphamine-induced (3 mM)
Ptc1 expression in NIH 3T3 fibroblasts (mean ±
SEM, n = 3, expression normalized to GAPDH;
p value < 0.003, starting at 1 mM). Related to
Figures S1 and S3.selectively reproduced the zebrafish Hh-null phenotype with fea-
tures ranging from ventral tail curvature, small eyes, loss of pec-
toral fins, and enlarged rounded somites to loss of neurocranial
chondrogenesis and impaired slow muscle formation (Figures
1B–1D; Barresi et al., 2000; van Eeden et al., 1996a, 1996b;
Wada et al., 2005; Hirsinger et al., 2004). Consistent with loss
of Hh signaling, we confirmed abrogation of the Hh-target
gene Patched (Ptc)-1 expression in bud-stage adaxial cells, pec-
toral fin fields, and somites resulting from eggmanone treatment
(Figures 1E and 1F).
Given that eggmanone elicited a loss-of-Hh phenotype in
zebrafish, we tested its ability to directly affect Hh signaling in
the mouse Hh reporter cell line Shh-Light2 (Taipale et al.,
2000). Eggmanone inhibited Hh-inducible Gli-responsive
luciferase (Gli-Luc) activity in a dose-dependent manner when
stimulated with the exogenous ligand Shh (Figure 1G). In
contrast, cells transiently overexpressing Gli2 retained Gli-Luc
activity following eggmanone treatment (Figure S1D). Moreover,
developmental signaling pathways such as bone morphogenic
protein (BMP) were not perturbed by eggmanone (Figure S1E).
Taken together, our results indicate that eggmanone pharma-
cologically targets an evolutionarily conserved component spe-
cifically in the Hh pathway upstream of Gli.44 Cell Reports 11, 43–50, April 7, 2015 ª2015 The AuthorsEggmanone Exerts Its Hh-Inhibitory Effects
Downstream of Smo
Considering that all new molecular entities registered with the
FDA to date for Hh-driven clinical trials target the cyclopamine
binding site of Smo, we examined eggmanone’s effects at the
level of Smo signaling (Trinh et al., 2014). Specifically, eggma-
none retained its Hh-inhibitory activity when Shh-Light2 cells
were stimulated with the Smo agonist purmorphamine, blocking
both Gli-Luc activity and Ptc1 expression (Figures 1H and 1I;
Sinha and Chen, 2006). Importantly, eggmanone failed to
compete for Smo binding with BODIPY-cyclopamine when
HEK293 cells overexpressing Smo were pre-treated with 5 nM
of the fluorescent ligand followed by treatment with concentra-
tions of eggmanone up to 10 mM (Figure S1F; Chen et al.,
2002a). Therefore, these results confirmed that eggmanone
targets the Hh pathway at or downstream of Smo.
To rule out its action at alternative Smo-binding sites, we
investigated eggmanone’s ability to inhibit Hh signaling in
Sufu/ mouse embryonic fibroblasts (MEFs), which display
constitutively active signaling downstream of Ptc and Smo
(Chen et al., 2009; Lin et al., 2014). Specifically, eggmanone
significantly reduced transcription levels of Gli1 and Ptc1,
whereas, as expected, the Smo antagonist cyclopamine showed
Figure 2. Eggmanone Alters the Activity of Gli Transcription Factors
(A) Quantitation of mRNA transcripts of Gli1 and Ptc1 in Sufu/ cells when treated with 10 mM Cyc (mean ± SEM, n = 7; not significant) or 10 mM Egm (mean ±
SEM, n = 10; ***p = < 0.0001) is given, expression normalized to GAPDH.
(B) Immunostaining for the cilium marker Arl13b (red) and Gli2 (green) of unstimulated MEFs (top), MEFs stimulated with SAG (20 nM) in the presence of DMSO
control (middle), or 5 mM Egm (bottom). Co-localization of Gli2 (yellow) in the primary cilium remained unchanged in Egm-treated MEFs. Representative cilium
(white box) is magnified to the right; scale bar (left column), 10 mm, (columns 2–4) 0.2 mm.
(C) Representative western blot for full-length Gli2 in nuclear (top, n = 4) and whole-cell (middle, n = 2) fractions of NIH 3T3 cells, and western blot of Gli3 (bottom,
n = 3) fromwhole-cell lysate of C3H10T1/2 cells. Corresponding western blots for nuclear Lamin-A/C andwhole-cell a-tubulin as loading controls are shown. Neg,
unstimulated; SAG, stimulated with SAG (100 nM) for 1.5 hr (Gli2) or 24 hr (Gli3); SAG + FSK, co-treated with SAG and FSK (30 mM); SAG + Egm, co-treated with
SAG and Egm (10 mM); FL, full-length active forms of Gli2 and Gli3; R, repressor form of Gli3.
(D) Quantitative analysis of the mean ratio of normalized nuclear full-length Gli2 to normalized whole-cell Gli2 from (C) is given.
(E) Quantitative analysis of the ratio of full-length to repressor form of Gli3 from (C) is given (mean ± SEM, n = 3 for each condition; **p = 0.0095, *p = 0.028 versus
SAG). Related to Figure S2.no inhibition (Figure 2A). Thus, taken in concert with our previous
findings, eggmanone acts between Smo and Gli-mediated tran-
scription to block Hh signaling.
Eggmanone Differentially Affects Gli Transcription
Factors
The primary cilium plays a critical role in Hh signal transduction
(Corbit et al., 2005; Rohatgi et al., 2007). Smo translocation to
the cilium propagates Hh pathway activation through the ciliary
trafficking of Gli (Wong et al., 2009). Therefore, we examined
whether eggmanone affected Gli trafficking to the primary cilium,
where Gli transcription factors undergo activation prior to pro-teolytic processing and subsequent translocation to the nucleus
to either promote or inhibit transcription (Haycraft et al., 2005; Liu
et al., 2005). Thus, under pathway stimulation with the Smo
agonist SAG (Frank-Kamenetsky et al., 2002; Chen et al.,
2002b), MEFs stained for Gli2 confirmed trafficking of Gli2 to
the primary cilium (Figure 2B). Importantly, with co-treatment
of SAG and eggmanone, Gli2 properly localized to the proximal
tip of the cilium as marked by the ciliary maintenance protein
Arl13b. Additionally, with the recent report of ciliobrevin D, a
small molecule that antagonizes the cytoplasmic motor dynein,
resulting in defective retrograde transport, and causes gross
ciliary malformation, we sought to examine whether eggmanoneCell Reports 11, 43–50, April 7, 2015 ª2015 The Authors 45
Figure 3. Eggmanone Modulates the Activity of PKA at the Basal Body
(A) Immunostaining for the cilia marker Arl13b (green) and the autophosphorylated form of the PKA catalytic subunit (phospho-T197-PKA; red) in NIH 3T3 cells
unstimulated (left) or stimulated with the Smo agonist SAG (20 nM, middle) demonstrated a low baseline PKA activation; co-treatment with SAG and Egm (5 mM,
right) increased local PKA activation at the base of the primary cilium. Representative cilium (white box) is magnified (inset). Scale bars, 10 mm.
(B) Quantitative analysis of the local activation of phospho-T197-PKA at the cilium (C) and peri-cilium (P) is given (mean ± SEM, n = 3 for each condition; *p = 0.031
versus SAG alone at the peri-cilium), as shown in (A).
(C) Western blot of NIH 3T3 whole-cell lysates for phospho-T197-PKA (bottom) and a-tubulin (top). SAG was treated at 20 nM and Egm at 5 mM.
(D) Immunostaining is shown for the basal body marker g-tubulin (green) and the autophosphorylated PKA catalytic subunit (phospho-T197-PKA; red) in NIH 3T3
cells unstimulated (top) or stimulated with SAG (20 nM, middle) and Egm (5 mM) (bottom). Scale bars, 10 mm.
(E) Quantitative analysis of p-PKA intensity at the basal body from (D) is given. RFU, relative fluorescence units (mean ± SEM, n = 21 for each condition;
***p = < 0.0001 versus SAG alone).affected cilium structure and trafficking (Hyman et al., 2009;
Firestone et al., 2012). In NIH 3T3 cells stained for the ciliary
maintenance protein Arl13b, cilium structure was unaffected
by eggmanone, and, in contrast to ciliobrevin D, the ciliary trans-
port protein IFT88 remained intact following eggmanone treat-
ment (Figure S2). Thus, in light of unaltered structure and ciliary
trafficking of Gli, we focused on elucidating eggmanone’s effects
on Gli processing and nuclear translocation.
Under regulation by Hh signaling, each Gli transcription factor
is differentially processed to form either Gli full-length (FL) activa-
tors or Gli repressors (R), which then translocate to the nucleus to
either activate or inhibit downstream gene transcription. How-
ever, the relative importance of Gli processing and nuclear
translocation varies between individual factors. For instance,
the differential processing of Gli3 is more sensitive to the Hh
pathway status than Gli2, which remains predominantly in its
GliFL form regardless of Hh activity (Hui and Angers, 2011).
Thus, we separately investigated Gli2FL nuclear accumulation
and proteolytic processing of Gli3FL to Gli3R. Hh pathway stim-
ulation with SAG led to an increase in the fraction of Gli2FL in the
nucleus, and this nuclear accumulation was inhibited by eggma-
none and the adenylyl cyclase (AC) activator forskolin (FSK) (Fig-
ures 2C and 2D). SAG treatment also inhibited processing of46 Cell Reports 11, 43–50, April 7, 2015 ª2015 The AuthorsGli3FL to Gli3R, and both eggmanone and FSK restored Gli3R
formation (Figures 2C and 2E; Humke et al., 2010). Taken
together, these data suggest that eggmanone functions up-
stream of Gli processing and nuclear translocation to exert its
Hh-inhibitory effects.
Eggmanone Causes Selective Activation of Protein
Kinase A at the Basal Body
An emerging understanding of Gli transcription factor activity in-
volves direct phosphorylation by protein kinase A (PKA) at two
separable steps: (1) repressor formation, and (2) activation for
nuclear translocation (Pan et al., 2009; Wolff et al., 2013; Tuson
et al., 2011; Wang et al., 1999; Zeng et al., 2010; Niewiadomski
et al., 2014). As our Gli2 and Gli3 western data (Figure 2) corre-
lated well with this picture, we next investigated eggmanone’s
effects on PKA autophosphorylation. Immunostaining and quan-
tification of phospho-threonine 197-PKA (p-T197-PKA) following
eggmanone treatment strikingly indicated a significant increase
in PKA activity at the base of the primary cilium, corresponding
to the basal body, when co-stained with the ciliary maintenance
protein Arl13b (Figures 3A and 3B). However, western blotting of
whole-cell lysates indicated no significant increase in p-PKA
levels upon eggmanone treatment (Figure 3C), hinting at the
Figure 4. Eggmanone Exerts Its Hedgehog-
Inhibitory Effects through Antagonism of
PDE4
(A) In vitro PDE activity assays across ten PDE
super-family members by Egm (20 mM) are listed.
(B) Dose-response curves of Egm against PDE4D3
(red), PDE3A (blue), PDE10A2 (purple), and
PDE11A4 (green). IC50s were 0.072, 3.00, 3.05,
and 4.08 mM, respectively. Error bars are reported
as SEM.
(C) Transient overexpression of wild-type (WT)
PDE4D3-induced Hh reporter activity (*p = 0.0026
versus pCS2 control), which was abolished by
5 mM Egm (p < 0.0001 versus PDE4D3 WT).
Transient overexpression of dominant-negative
(DN) PDE4D3 decreased Hh reporter activity (*p =
0.0121 versus pCS2 control). Data are reported as
mean ± SEM.
(D) Rolipram (Rol) inhibited Sonic hedgehog (Shh)-
responsive Gli-luciferase (Gli-Luc) reporter activity
when stimulated with Shh-conditioned medium
(n = 4 for each condition, results represented as
mean RLU ± SEM; p value < 0.003, starting at
1 mM). Related to Tables S1, S2, and S3.possibility of localized PKA activation by eggmanone. PKA’s
localization to the basal body has been reported previously as
a mechanism for control of Gli processing prior to its trafficking
to the nucleus to inhibit Hh signaling (Tuson et al., 2011).
To confirm this localization, co-staining of p-T197-PKA and
g-tubulin, which associates with the basal body, further revealed
robust PKA activation at the basal body due to eggmanone treat-
ment (Figures 3D and 3E). Taken together with theGli processing
and translocation data, localized PKA activation may be respon-
sible for mediating eggmanone’s effects on Hh signaling.
Eggmanone Inhibits Phosphodiesterase 4
PKA is anchored to the basal body by A kinase-anchoring pro-
teins (AKAPs) and is activated in response to the ubiquitous sec-
ondary messenger cyclic adenosine monophosphate (cAMP)
(Terrin et al., 2012). Cyclic AMP is synthesized by ACs, but,
most importantly, its levels are controlled through its degradation
by phosphodiesterases (PDEs). Following this logic, we hypoth-
esized that eggmanone may antagonize Hh signaling by PDE in-
hibition. In a screen of PDE super-family members, eggmanone
potently inhibited PDE4D3 and the activity of three other mem-
bers by 50% or greater at 20 mM (Figure 4A). In a dose-response
assay with these four classes of PDEs, eggmanone displayed
potent antagonism of PDE4D3 with an IC50 of 0.072 mM, approx-
imately 40- to 50-fold selective over other PDEs (Figure 4B).
Lending further validity to PDE4 as eggmanone’s cellular target,
PDE4D3 has been shown to complex with PKA and AKAP9 atCell Reports 11, 4the centrosome (Terrin et al., 2012). Addi-
tionally, a counter-screen of eggmanone
against a broad andcomprehensive panel
of 442 kinases, 158 GPCRs, and 21 phos-
phatases revealed that no other targets
were inhibited by eggmanone by greater
than 50% (Tables S1, S2, and S3). Basedon these results, we conclude that eggmanone is a potent and
selective PDE4 inhibitor.
PDE4 Modulates Hh Signaling In Vitro
Considering the previous lack of direct correlation between PDE
inhibition andHhblockade, we sought tomolecularly confirm this
association. First, the PDE isoform most potently inhibited
by eggmanone, PDE4D3, was transfected into Shh-Light2
cells and significantly increased Hh signaling (Figure 4C). This
increased signaling was returned to basal level upon treatment
with eggmanone. Furthermore, transfection of a dominant-nega-
tive catalytically inactive PDE4D3 construct led to a reduction in
Hh signaling, which was further abrogated by subsequent egg-
manone treatment (Figure 4C). Finally, if PDE inhibition modu-
lates Hh signaling, we reasoned that the broad-spectrum PDE4
inhibitor rolipram should display inhibitory activity in the Gli-Luc
reporter assay. Indeed, stimulating Shh-Light2 cells with Shh fol-
lowed by treatment with increasing concentrations of rolipram
did reduce Hh signaling levels, albeit with lower potency than
eggmanone (Figure 4D). These results confirm that decreased
cAMP concentrations due to higher PDE4 activity can promote
Hh signaling, and the converse situation can lead toHh inhibition.
DISCUSSION
Hh and PDE4 have been independently identified as promising
targets for cancer therapy. As previously mentioned, Hh3–50, April 7, 2015 ª2015 The Authors 47
signaling has been shown to drive tumor progression in BCC,
medulloblastoma, and other cancers (Kar et al., 2012; Ng and
Curran, 2011). PDE4 primarily has been implicated as a driver
of CNS tumors, such as medulloblastoma and glioblastoma, as
well as lung and breast tumors (Goldhoff et al., 2008; Sengupta
et al., 2011). Moreover, much evidence points to overexpression
of PDE4 in a wide variety of tumors, and the resulting decrease in
cAMP has been associated with increased prevalence of malig-
nancies. Finally, recent studies have lent credence to PDE inhibi-
tion as relevant for Hh-driven cancers, but have yet to elucidate
the precise mechanism of action (He et al., 2014; Powers et al.,
2015).
Our results demonstrate that eggmanone functions as a PDE4
inhibitor to inhibit Hh signaling downstream of Smo, the singular
target of the currently FDA-approved Hh inhibitor vismodegib as
well as Hh inhibitors being evaluated in clinical trials. Addition-
ally, our data corroborate earlier studies that PKA plays an
essential yet incompletely understood role in the regulation of
Hh signals. Earlier studies found that the global PKA activator
FSK abrogated Gli translocation to the primary cilium, in contrast
to eggmanone, which does not disrupt Gli2 ciliary trafficking
(Tukachinsky et al., 2010). We attribute this and other differences
between eggmanone and FSK to the possibility that FSK’s effect
on Gli ciliary trafficking may be unrelated to PKA activation. For
instance, FSK blocks Gli2 ciliary localization in PKA/ cells
(Tuson et al., 2011) and inhibits translocation of phosphomimetic
forms of Gli2 to the cilium, even though the status of Gli phos-
phorylation by PKA does not affect Gli ciliary localization (Zeng
et al., 2010). Ultimately, our results indicate that PKA activation
by eggmanone disrupts a process downstream of Gli ciliary
trafficking, which is further supported by our finding that eggma-
none can inhibit Hh signaling downstream of Sufu, a key regu-
lator of Gli distribution.
While the cellular effects of PKA traditionally have been viewed
in the context of global signaling, recent studies highlight the
importance of PKA localization in Hh regulation (Barzi et al.,
2010; Niewiadomski et al., 2013). Consistent with the latter
view, our study with eggmanone suggests that PKA activation
at the basal body functions to regulate Gli processing and trans-
location after transit through the primary cilium, where PDE4 re-
sides in the basal body complex to control local levels of cAMP
and thus PKA activity. In contrast to FSK, eggmanone can be
considered as a unique probe of localized PKA signaling, and
our studies lend further validity to the unbiased in vivo chemical
genetic screen for identifying valuable chemical biology tools.
Importantly, we have further validated the concept of PDE4 as
an important therapeutic target for Hh-driven cancers down-
stream of Smo, and we have suggested a mechanism for
PDE4 regulation of Hh signals.
EXPERIMENTAL PROCEDURES
All zebrafish experiments were approved by the Vanderbilt University Institu-
tional Animal Care and Use Committee.
Chemical Screen
Chemical screening for small molecules that perturb zebrafish embryonic
development was performed as previously described (Hao et al., 2010;
Hong, 2009) and is detailed in the Supplemental Experimental Procedures.48 Cell Reports 11, 43–50, April 7, 2015 ª2015 The AuthorsEggmanone Synthesis
Methods for synthesis of eggmanone are detailed in the Supplemental Exper-
imental Procedures and the synthetic scheme is represented in Figure S3.
Whole-Mount Zebrafish In Situ Hybridization
In situ hybridization was performed as previously described (Westerfield,
2000). ZebrafishPtc1 probes were produced as previously described (Concor-
det et al., 1996).
Immunocytochemistry
NIH 3T3 cells seeded on coated coverslips were treated with SAG (20 nM) in
the presence or absence of Egm (5 mM). Cells with no SAG treatment served
as a control. Cells were fixed, permeabilized, and stained for appropriate pro-
teins. A more detailed protocol with antibody descriptions is detailed in the
Supplemental Experimental Procedures.
Protein Isolation and Western Blotting
Unstimulated cells or cells treated with SAG (100 nM) in the presence or
absence of Egm (10 mM) or FSK (30 mM) were lysed to obtain total cellular pro-
tein or fractionated for nuclear/cytoplasmic proteins. After separation and
transfer, blots were incubated with primary then secondary antibodies. Blots
were visualized using a LI-COR Biosciences Odyssey system. Amore detailed
protocol with antibody descriptions is detailed in the Supplemental Experi-
mental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.03.001.
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